Text and Data Mining valid from 2017-09-01
Received: 18 November 2016
Accepted: 4 July 2017
First Online: 1 September 2017
: Professor Drakesmith declares research funding from Pfizer and consultancy with Kymab. Professor Draper declares research funding from Pfizer. Professor Rivella declares consultancies for Novartis and Ionis. Professor Milne is a shareholder of Oxstem Oncology (OSO), a subsidiary company of OxStem Ltd. The remaining authors declare no competing financial interests.